Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting
Hypomagnesemia is a well-recognised complication of cis-diamminedichloroplatinum (DDP) treatment. We prospectively evlauated 50 patients with advanced malignant disease receiving DDP for the development of hypomagnesemia. Urinary magnesium excretion was measured in 24 patients. The mean serum magnes...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1985-03, Vol.21 (3), p.287-290 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 290 |
|---|---|
| container_issue | 3 |
| container_start_page | 287 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 21 |
| creator | Bell, David R Woods, Robert L Levi, John A |
| description | Hypomagnesemia is a well-recognised complication of
cis-diamminedichloroplatinum (DDP) treatment. We prospectively evlauated 50 patients with advanced malignant disease receiving DDP for the development of hypomagnesemia. Urinary magnesium excretion was measured in 24 patients. The mean serum magnesium fell from 0.79
mmol/l (normal 0.7–1.1
mmol/l) prior to therapy to 0.55
mmol/l 3
months after commencing DDP. All 50 patients had become hypomagnesemic by this time and 10% were symptomatic, requiring oral magnesium supplementation. At 6
weeks after commencing DDP only four patients had restricted urinary magnesium excretion to less than 1.0
mmol/day. The other patients clearly had inappropriately high levels of urinary magnesium excretion, suggesting that DDP may induce a renal tubular defect in magnesium conservation. Hypomagnesemia is a common complication of DDP therapy which in many patients is asymptomatic. Further, more detailed studies of renal magnesium handling are necessary to determine fully the effect of DDP on urinary magnesium excretion. |
| doi_str_mv | 10.1016/0277-5379(85)90127-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_14363717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537985901270</els_id><sourcerecordid>14363717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-4abc499b54539428379a20fd0e812293d77d70d61afe074d8e419c638bed59043</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxT2ASil8A5AyIARDwI6dOF6QUMU_qVIXmC3XvrRGsVPsBtRvj0Orjkynu3vv7umH0AXBdwST6h4XnOcl5eKmLm8FJgXP8REaH8Yn6DTGT4yLmpV0hEYMs9TgMZpPbcyNVc5ZD8bqVduFbt2qjfW9y603vQaTrbbrzqmlhwjOqkx5kwXwqs12Q9u77EfF5FmeoeNGtRHO93WCPp6f3qev-Wz-8jZ9nOWa1XSTM7XQTIhFmeIIVtQpoipwYzDUpCgENZwbjk1FVAOYM1MDI0JXtF6AKQVmdIKud3fXofvqIW6ks1FD2yoPXR8lYbSinPAkZDuhDl2MARq5DtapsJUEy4GdHCDJAZKsS_nHTuJku9zf7xcOzMG0B5f2V_u9ilq1TVBe23iQiaIqGR2-P-xkkFh8Wwgyags-MbUB9Eaazv6f4xf3JIzn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14363717</pqid></control><display><type>article</type><title>Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bell, David R ; Woods, Robert L ; Levi, John A</creator><creatorcontrib>Bell, David R ; Woods, Robert L ; Levi, John A</creatorcontrib><description>Hypomagnesemia is a well-recognised complication of
cis-diamminedichloroplatinum (DDP) treatment. We prospectively evlauated 50 patients with advanced malignant disease receiving DDP for the development of hypomagnesemia. Urinary magnesium excretion was measured in 24 patients. The mean serum magnesium fell from 0.79
mmol/l (normal 0.7–1.1
mmol/l) prior to therapy to 0.55
mmol/l 3
months after commencing DDP. All 50 patients had become hypomagnesemic by this time and 10% were symptomatic, requiring oral magnesium supplementation. At 6
weeks after commencing DDP only four patients had restricted urinary magnesium excretion to less than 1.0
mmol/day. The other patients clearly had inappropriately high levels of urinary magnesium excretion, suggesting that DDP may induce a renal tubular defect in magnesium conservation. Hypomagnesemia is a common complication of DDP therapy which in many patients is asymptomatic. Further, more detailed studies of renal magnesium handling are necessary to determine fully the effect of DDP on urinary magnesium excretion.</description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(85)90127-0</identifier><identifier>PMID: 4040020</identifier><identifier>CODEN: EJCODS</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Drug Administration Schedule ; Drug toxicity and drugs side effects treatment ; Female ; Humans ; Kidney - metabolism ; Magnesium - blood ; Magnesium - metabolism ; Magnesium - urine ; Magnesium Deficiency - chemically induced ; Magnesium Deficiency - metabolism ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Prospective Studies</subject><ispartof>European journal of cancer & clinical oncology, 1985-03, Vol.21 (3), p.287-290</ispartof><rights>1985</rights><rights>1985 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-4abc499b54539428379a20fd0e812293d77d70d61afe074d8e419c638bed59043</citedby><cites>FETCH-LOGICAL-c483t-4abc499b54539428379a20fd0e812293d77d70d61afe074d8e419c638bed59043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9265437$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4040020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bell, David R</creatorcontrib><creatorcontrib>Woods, Robert L</creatorcontrib><creatorcontrib>Levi, John A</creatorcontrib><title>Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description>Hypomagnesemia is a well-recognised complication of
cis-diamminedichloroplatinum (DDP) treatment. We prospectively evlauated 50 patients with advanced malignant disease receiving DDP for the development of hypomagnesemia. Urinary magnesium excretion was measured in 24 patients. The mean serum magnesium fell from 0.79
mmol/l (normal 0.7–1.1
mmol/l) prior to therapy to 0.55
mmol/l 3
months after commencing DDP. All 50 patients had become hypomagnesemic by this time and 10% were symptomatic, requiring oral magnesium supplementation. At 6
weeks after commencing DDP only four patients had restricted urinary magnesium excretion to less than 1.0
mmol/day. The other patients clearly had inappropriately high levels of urinary magnesium excretion, suggesting that DDP may induce a renal tubular defect in magnesium conservation. Hypomagnesemia is a common complication of DDP therapy which in many patients is asymptomatic. Further, more detailed studies of renal magnesium handling are necessary to determine fully the effect of DDP on urinary magnesium excretion.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney - metabolism</subject><subject>Magnesium - blood</subject><subject>Magnesium - metabolism</subject><subject>Magnesium - urine</subject><subject>Magnesium Deficiency - chemically induced</subject><subject>Magnesium Deficiency - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxT2ASil8A5AyIARDwI6dOF6QUMU_qVIXmC3XvrRGsVPsBtRvj0Orjkynu3vv7umH0AXBdwST6h4XnOcl5eKmLm8FJgXP8REaH8Yn6DTGT4yLmpV0hEYMs9TgMZpPbcyNVc5ZD8bqVduFbt2qjfW9y603vQaTrbbrzqmlhwjOqkx5kwXwqs12Q9u77EfF5FmeoeNGtRHO93WCPp6f3qev-Wz-8jZ9nOWa1XSTM7XQTIhFmeIIVtQpoipwYzDUpCgENZwbjk1FVAOYM1MDI0JXtF6AKQVmdIKud3fXofvqIW6ks1FD2yoPXR8lYbSinPAkZDuhDl2MARq5DtapsJUEy4GdHCDJAZKsS_nHTuJku9zf7xcOzMG0B5f2V_u9ilq1TVBe23iQiaIqGR2-P-xkkFh8Wwgyags-MbUB9Eaazv6f4xf3JIzn</recordid><startdate>198503</startdate><enddate>198503</enddate><creator>Bell, David R</creator><creator>Woods, Robert L</creator><creator>Levi, John A</creator><general>Elsevier Ltd</general><general>Pergamon Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>198503</creationdate><title>Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting</title><author>Bell, David R ; Woods, Robert L ; Levi, John A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-4abc499b54539428379a20fd0e812293d77d70d61afe074d8e419c638bed59043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney - metabolism</topic><topic>Magnesium - blood</topic><topic>Magnesium - metabolism</topic><topic>Magnesium - urine</topic><topic>Magnesium Deficiency - chemically induced</topic><topic>Magnesium Deficiency - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><toplevel>online_resources</toplevel><creatorcontrib>Bell, David R</creatorcontrib><creatorcontrib>Woods, Robert L</creatorcontrib><creatorcontrib>Levi, John A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bell, David R</au><au>Woods, Robert L</au><au>Levi, John A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1985-03</date><risdate>1985</risdate><volume>21</volume><issue>3</issue><spage>287</spage><epage>290</epage><pages>287-290</pages><issn>0277-5379</issn><coden>EJCODS</coden><abstract>Hypomagnesemia is a well-recognised complication of
cis-diamminedichloroplatinum (DDP) treatment. We prospectively evlauated 50 patients with advanced malignant disease receiving DDP for the development of hypomagnesemia. Urinary magnesium excretion was measured in 24 patients. The mean serum magnesium fell from 0.79
mmol/l (normal 0.7–1.1
mmol/l) prior to therapy to 0.55
mmol/l 3
months after commencing DDP. All 50 patients had become hypomagnesemic by this time and 10% were symptomatic, requiring oral magnesium supplementation. At 6
weeks after commencing DDP only four patients had restricted urinary magnesium excretion to less than 1.0
mmol/day. The other patients clearly had inappropriately high levels of urinary magnesium excretion, suggesting that DDP may induce a renal tubular defect in magnesium conservation. Hypomagnesemia is a common complication of DDP therapy which in many patients is asymptomatic. Further, more detailed studies of renal magnesium handling are necessary to determine fully the effect of DDP on urinary magnesium excretion.</abstract><cop>Oxford</cop><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>4040020</pmid><doi>10.1016/0277-5379(85)90127-0</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1985-03, Vol.21 (3), p.287-290 |
| issn | 0277-5379 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_14363717 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Biological and medical sciences Cisplatin - administration & dosage Cisplatin - adverse effects Drug Administration Schedule Drug toxicity and drugs side effects treatment Female Humans Kidney - metabolism Magnesium - blood Magnesium - metabolism Magnesium - urine Magnesium Deficiency - chemically induced Magnesium Deficiency - metabolism Male Medical sciences Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Neoplasms - drug therapy Pharmacology. Drug treatments Prospective Studies |
| title | Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A01%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cis-diamminedichloroplatinum-induced%20hypomagnesemia%20and%20renal%20magnesium%20wasting&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Bell,%20David%20R&rft.date=1985-03&rft.volume=21&rft.issue=3&rft.spage=287&rft.epage=290&rft.pages=287-290&rft.issn=0277-5379&rft.coden=EJCODS&rft_id=info:doi/10.1016/0277-5379(85)90127-0&rft_dat=%3Cproquest_cross%3E14363717%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14363717&rft_id=info:pmid/4040020&rft_els_id=0277537985901270&rfr_iscdi=true |